MagForce AG

04.07.2018 - Equity Research Einzelstudie // buy

Research Comment – MagForce AG - english

pdf For the original study, please click here
Unternehmen: MagForce AG
Branche: Biotechnologie-Pharma
Rating: buy
Kurs bei Erstellung in €: 4,67
Kursziel in €: 15,80
Mögl. Interessenskonflikt gem. §34b Abs.1 WpHG und FinAnv: 5a;6a;11

The company announced on the 02/07/2018 that it has enrolled the first patient in its clinical evaluation with the Company’s innovative NanoTherm selective ablation. This represents an important milestone in the history of the company and should make a significant contribution to the future development of the US market.

The purpose of this registration study is to demonstrate that NanoTherm therapy can focally ablate cancer lesions with minimal side effects for patients who have progressed to intermediate risk prostate cancer stage. The objective of the new cancer treatment is to establish itself as a further pillar of cancer therapy alongside conventional treatment methods such as surgery, radiation and chemotherapy.


Wichtiger Hinweis:

Bitte beachten Sie den Disclaimer/Risikohinweis sowie die Offenlegung möglicher Interessenskonflikte nach §34b WpHG /FinAnV auf unserer Webseite.